Two clinical trials of an off-the-shelf CAR-T cancer therapy from Cellectis (CLLS) have been placed on clinical hold following the death of a patient caused by a severe toxic reaction to the treatment.

Cellectis’ stock price is down 30 percent to $22.79 in early Tuesday trading. The biotech company, with operations in Paris and New York, announced the FDA clinical hold on Sunday night.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy